Literature DB >> 16411070

Combined treatment of invasive giant prolactinomas.

Chonjiang Yu1, Zhebao Wu, Jian Gong.   

Abstract

The management of invasive giant prolactinomas (IGP) has been an area of some controversy. The relative roles of transsphenoidal surgery, craniotomy, radiation therapy and dopamine agonist based medical therapy are gradually becoming clarified. We report the results of management of 30 patients with IGP. Surgery was the initial therapy in 18 patients and was nearly always followed by adjunctive treatment with radiotherapy and/or bromocriptine. A second group of 12 patients had initial therapy with bromocriptine; 6 had subsequent radiotherapy and only 1 had transsphenoidal surgery. Outcomes with regard to relief of mass effect, visual improvement, pituitary function and complications of therapy were superior in the bromocriptine treated patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16411070     DOI: 10.1007/s11102-005-5087-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  18 in total

1.  Large macroprolactinoma treated with bromocriptine alone.

Authors:  K C Loh; A H Shlossberg
Journal:  Ann Acad Med Singapore       Date:  1996-11       Impact factor: 2.473

2.  Giant invasive prolactinoma: a case report and review of nine further cases.

Authors:  J R Davis; M C Sheppard; D A Heath
Journal:  Q J Med       Date:  1990-03

3.  Clinical features and medical treatment of male prolactinomas.

Authors:  S Asano; K Ueki; I Suzuki; T Kirino
Journal:  Acta Neurochir (Wien)       Date:  2001       Impact factor: 2.216

4.  Giant prolactinomas presenting as skull base tumors.

Authors:  Giuseppe Minniti; Marie Lise Jaffrain-Rea; Antonio Santoro; Vincenzo Esposito; Luigi Ferrante; Roberto Delfini; Giampaolo Cantore
Journal:  Surg Neurol       Date:  2002-02

5.  A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma.

Authors:  S Acquati; A Pizzocaro; G Tomei; M Giovanelli; R Libè; G Faglia; B Ambrosi
Journal:  J Neurosurg Sci       Date:  2001-06       Impact factor: 2.279

6.  The neurosurgical management of prolactinomas.

Authors:  H Z Gökalp; H Deda; A Attar; H C Uğur; E Arasil; N Egemen
Journal:  J Neurosurg Sci       Date:  2000-09       Impact factor: 2.279

7.  Visual function in prolactinoma patients treated with bromocriptine.

Authors:  M L Moster; P J Savino; N J Schatz; P J Snyder; R C Sergott; T M Bosley
Journal:  Ophthalmology       Date:  1985-10       Impact factor: 12.079

8.  Extrasellar prolactinomas: successful management of 24 patients using bromocriptine.

Authors:  J O Sieck; N L Niles; J R Jinkins; O Al-Mefty; S el-Akkad; N Woodhouse
Journal:  Horm Res       Date:  1986

9.  Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas.

Authors:  J C Mbanya; A D Mendelow; P J Crawford; K Hall; J H Dewar; P Kendall-Taylor
Journal:  Br J Neurosurg       Date:  1993       Impact factor: 1.596

Review 10.  [The role of surgery in the treatment of prolactinomas].

Authors:  F X Roux; F Nataf; P Page; B Devaux; F Brami
Journal:  Gynecol Obstet Fertil       Date:  2002-05
View more
  9 in total

1.  Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Samuel Shin; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

2.  Multidisciplinary treatment of giant invasive prolactinomas in paediatric age: long-term follow-up in two children.

Authors:  Mario Francesco Fraioli; Federica Novegno; Elisabetta Catena; Chiara Fraioli; Laura Moschettoni
Journal:  Childs Nerv Syst       Date:  2010-03-30       Impact factor: 1.475

3.  Long-term outcome of multimodal therapy for giant prolactinomas.

Authors:  Paula Andujar-Plata; Rocio Villar-Taibo; Maria Dolores Ballesteros-Pomar; Alfonso Vidal-Casariego; Begoña Pérez-Corral; Jose Manuel Cabezas-Agrícola; Paula Álvarez-Vázquez; Ramón Serramito; Ignacio Bernabeu
Journal:  Endocrine       Date:  2016-10-04       Impact factor: 3.633

4.  Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.

Authors:  Susana Mascarell; David H Sarne
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

5.  Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist.

Authors:  Moon Sool Yang; Jae Won Hong; Seung Koo Lee; Eun Jig Lee; Sun Ho Kim
Journal:  J Neurooncol       Date:  2010-11-24       Impact factor: 4.130

Review 6.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

7.  Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.

Authors:  Zhe Bao Wu; Zhi Peng Su; Jin Sen Wu; Wei Ming Zheng; Qi Chuan Zhuge; Ming Zhong
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.

Authors:  Zhe Bao Wu; Wei Ming Zheng; Zhi Peng Su; Yong Chen; Jin Sen Wu; Cheng De Wang; Chen Lin; Yan Jun Zeng; Qi Chuan Zhuge
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

9.  Cure and Hormonal Control After Prolactinoma Resection: Case Series and Systematic Review.

Authors:  Marisa C Penn; Tyler Cardinal; Yanchen Zhang; Brittany Abt; Phillip A Bonney; Patricia Lorenzo; Michelle Lin; Jack Rosner; Martin Weiss; Gabriel Zada; John D Carmichael
Journal:  J Endocr Soc       Date:  2021-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.